CA3045090A1 - Risk factor monitoring - Google Patents
Risk factor monitoring Download PDFInfo
- Publication number
- CA3045090A1 CA3045090A1 CA3045090A CA3045090A CA3045090A1 CA 3045090 A1 CA3045090 A1 CA 3045090A1 CA 3045090 A CA3045090 A CA 3045090A CA 3045090 A CA3045090 A CA 3045090A CA 3045090 A1 CA3045090 A1 CA 3045090A1
- Authority
- CA
- Canada
- Prior art keywords
- sample
- excitation
- input signal
- species
- risk factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012544 monitoring process Methods 0.000 title description 5
- 239000012491 analyte Substances 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 72
- 238000005259 measurement Methods 0.000 claims abstract description 67
- 230000005284 excitation Effects 0.000 claims abstract description 58
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 67
- 239000008103 glucose Substances 0.000 claims description 67
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 57
- 239000008280 blood Substances 0.000 claims description 57
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 56
- 229940116269 uric acid Drugs 0.000 claims description 56
- 230000004044 response Effects 0.000 claims description 55
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 54
- 239000003153 chemical reaction reagent Substances 0.000 claims description 41
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 238000007254 oxidation reaction Methods 0.000 claims description 19
- 230000003647 oxidation Effects 0.000 claims description 18
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- 238000012806 monitoring device Methods 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 7
- 238000006479 redox reaction Methods 0.000 claims description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960003638 dopamine Drugs 0.000 claims description 5
- 229960005489 paracetamol Drugs 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000000523 sample Substances 0.000 description 116
- 241000894007 species Species 0.000 description 92
- 206010012601 diabetes mellitus Diseases 0.000 description 20
- 238000005534 hematocrit Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 238000000835 electrochemical detection Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 238000003487 electrochemical reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Electrochemistry (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430232P | 2016-12-05 | 2016-12-05 | |
| US62/430,232 | 2016-12-05 | ||
| PCT/IB2017/057584 WO2018104835A1 (en) | 2016-12-05 | 2017-12-01 | Risk factor monitoring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3045090A1 true CA3045090A1 (en) | 2018-06-14 |
Family
ID=60788637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3045090A Abandoned CA3045090A1 (en) | 2016-12-05 | 2017-12-01 | Risk factor monitoring |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11353417B2 (enExample) |
| EP (1) | EP3548881A1 (enExample) |
| JP (1) | JP7074753B2 (enExample) |
| CN (1) | CN110249219B (enExample) |
| CA (1) | CA3045090A1 (enExample) |
| WO (1) | WO2018104835A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4054423A1 (en) * | 2019-11-07 | 2022-09-14 | Smylio Inc. | Saliva collection and testing system |
| TWI887462B (zh) * | 2020-08-04 | 2025-06-21 | 瑞士商安晟信醫療科技控股公司 | 生物感測器系統和在連續葡萄糖監測測量期間確定葡萄糖值的方法 |
| CN114242253B (zh) * | 2022-02-21 | 2022-05-17 | 深圳大学 | 一种用于糖尿病酮症酸中毒预警的健康管理方法及系统 |
| CN118111933B (zh) * | 2023-10-31 | 2025-04-04 | 南方医科大学南方医院 | 基于尿酸单钠晶体生长速率评估痛风发作风险的设备 |
| CN120232970A (zh) * | 2023-12-28 | 2025-07-01 | 江苏鱼跃凯立特生物科技有限公司 | 一种血糖浓度计算方法及传感器 |
| CN120232968A (zh) * | 2023-12-28 | 2025-07-01 | 江苏鱼跃凯立特生物科技有限公司 | 一种测试生物样品中分析物的方法、传感器及系统 |
| CN119355066A (zh) * | 2024-10-24 | 2025-01-24 | 江苏鱼跃凯立特生物科技有限公司 | 一种基于多激励方式测试生物样品中分析物浓度的方法和传感器 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004028887A (ja) * | 2002-06-27 | 2004-01-29 | Yamaguchi Technology Licensing Organization Ltd | 分子鋳型膜を利用したコレステロールセンサの開発およびそれを用いる非侵襲的なコレステロール計測法および機器 |
| CN100432660C (zh) * | 2003-05-07 | 2008-11-12 | 黄椿木 | 抛弃式电化学式感测试片的结构及其制作方法 |
| US9372190B2 (en) * | 2004-05-26 | 2016-06-21 | Region Nordjylland | Method of evaluation of the relative risk of developing atherosclerosis in patients |
| JP5009897B2 (ja) | 2005-04-08 | 2012-08-22 | バイエル・ヘルスケア・エルエルシー | バイオセンサのためのコントロール溶液中の内部基準としての酸化可能種 |
| KR101321296B1 (ko) | 2005-07-20 | 2013-10-28 | 바이엘 헬스케어 엘엘씨 | 게이트형 전류 측정법 온도 결정 방법 |
| KR101477947B1 (ko) | 2005-09-30 | 2014-12-30 | 바이엘 헬스케어 엘엘씨 | 게이트형 전압 전류 측정 이온화제 및 헤마토크리트 결정 방법 |
| EP2020909A2 (en) * | 2006-05-08 | 2009-02-11 | Bayer HealthCare LLC | Abnormal output detection system for a biosensor |
| BRPI0717620A2 (pt) | 2006-10-24 | 2013-10-22 | Bayer Healthcare Llc | Amperometria de decaimento transitório |
| CN107576707B (zh) | 2007-09-24 | 2020-03-13 | 安晟信医疗科技控股公司 | 分析物测试传感器及其系统和测量至少一种分析物的方法 |
| CN101896619B (zh) * | 2007-12-10 | 2017-04-05 | 安晟信医疗科技控股公司 | 速读门控电流分析法 |
| CN103760356B (zh) | 2007-12-10 | 2019-06-28 | 安晟信医疗科技控股公司 | 斜率式补偿 |
| US20090305317A1 (en) * | 2008-06-05 | 2009-12-10 | Brauer Jacob S | User interface for testing device |
| ES2700861T3 (es) * | 2008-07-10 | 2019-02-19 | Ascensia Diabetes Care Holdings Ag | Sistemas y métodos que incluyen ciclos de trabajo amperométricos y voltamétricos |
| JP5738770B2 (ja) * | 2008-12-08 | 2015-06-24 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ | 信号調整を持つバイオセンサシステム |
| MX368104B (es) | 2010-03-22 | 2019-09-19 | Ascensia Diabetes Care Holdings Ag | Compensacion residual para un biosensor. |
| SG186179A1 (en) | 2010-06-07 | 2013-01-30 | Bayer Healthcare Llc | Slope-based compensation including secondary output signals |
| CA3047242A1 (en) * | 2010-06-07 | 2011-12-15 | Ascensia Diabetes Care Holdings Ag | Underfill management system for a biosensor |
| US8615366B2 (en) * | 2010-10-15 | 2013-12-24 | Roche Diagnostics Operations, Inc. | Handheld diabetes management device with bolus calculator |
| JP2012247338A (ja) * | 2011-05-30 | 2012-12-13 | Gunze Ltd | 計測表示装置 |
| WO2013043839A1 (en) * | 2011-09-21 | 2013-03-28 | Bayer Healthcare Llc | Biosensor with error compensation |
| US20130116526A1 (en) | 2011-11-09 | 2013-05-09 | Telcare, Inc. | Handheld Blood Glucose Monitoring Device with Messaging Capability |
| JP2013242171A (ja) * | 2012-05-18 | 2013-12-05 | Tanita Corp | 濃度測定装置 |
| MX355854B (es) * | 2012-07-27 | 2018-05-03 | Ascensia Diabetes Care Holdings Ag | Sistema y metodo para detectar sensores utilizados y secados. |
| US9244036B2 (en) * | 2012-11-16 | 2016-01-26 | Cilag Gmbh International | System and method for determination of a concentration of at least one interfering substance and correction of glucose concentration based on the concentration of the interfering substance |
| HK1221771A1 (zh) | 2013-03-14 | 2017-06-09 | 安晟信医疗科技控股公司 | 分析物浓度测定的标准化校准 |
| JP6282636B2 (ja) * | 2013-04-26 | 2018-02-21 | パナソニックヘルスケアホールディングス株式会社 | 液体試料測定装置、液体試料測定方法、及び、バイオセンサ |
| WO2015004900A1 (ja) | 2013-07-08 | 2015-01-15 | パナソニックヘルスケア株式会社 | 血液成分の測定装置、血液成分の測定方法 |
| KR102460386B1 (ko) * | 2014-04-28 | 2022-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 환자 준수상태를 모니터하고 촉진하기 위한 눈에 잘 띄지 않는 무선 전자 시스템 |
| CN109690304A (zh) | 2016-07-12 | 2019-04-26 | 安晟信医疗科技控股公司 | 通过使用来自两个电极的交替输出信号进行电化学分析的方法 |
-
2017
- 2017-12-01 CA CA3045090A patent/CA3045090A1/en not_active Abandoned
- 2017-12-01 CN CN201780085383.9A patent/CN110249219B/zh active Active
- 2017-12-01 JP JP2019530087A patent/JP7074753B2/ja active Active
- 2017-12-01 EP EP17818627.6A patent/EP3548881A1/en not_active Ceased
- 2017-12-01 US US16/466,938 patent/US11353417B2/en active Active
- 2017-12-01 WO PCT/IB2017/057584 patent/WO2018104835A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20190346399A1 (en) | 2019-11-14 |
| WO2018104835A1 (en) | 2018-06-14 |
| EP3548881A1 (en) | 2019-10-09 |
| CN110249219A (zh) | 2019-09-17 |
| JP7074753B2 (ja) | 2022-05-24 |
| CN110249219B (zh) | 2022-08-23 |
| JP2019537026A (ja) | 2019-12-19 |
| WO2018104835A9 (en) | 2019-05-09 |
| US11353417B2 (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11353417B2 (en) | Risk factor monitoring | |
| JP6448504B2 (ja) | 勾配ベース補正 | |
| RU2745479C1 (ru) | Способ и блок электроники для определения свойств биосенсора в условиях in vivo | |
| KR101423851B1 (ko) | Ａｃ 측정 방법들에 기초한 샘플 특성화 | |
| JP5856154B2 (ja) | 二次出力シグナルを含む勾配に基づく補正 | |
| JP5738770B2 (ja) | 信号調整を持つバイオセンサシステム | |
| Cohn et al. | Assessment of five portable blood glucose meters, a point-of-care analyzer, and color test strips for measuring blood glucose concentration in dogs | |
| CA2794978C (en) | Analyte measurement method and system | |
| US11268925B2 (en) | Intertwined electrical input signals | |
| JP2011506966A5 (enExample) | ||
| JP2013528289A5 (enExample) | ||
| JP2012511160A5 (enExample) | ||
| RU2684938C2 (ru) | Система и способ определения концентраций глюкозы, нечувствительных к гематокриту | |
| KR20150036731A (ko) | 포도당 바이오센서 내의 간섭물을 처리하기 위한 시스템 및 방법 | |
| JP6309011B2 (ja) | ヘマトクリット非感受性グルコース濃度を判定するためのシステム及び方法 | |
| HK40015023A (en) | Risk factor monitoring | |
| Vokounová-Honsová et al. | The accuracy of continuous glucose monitoring system by the athlete with diabetes mellitus type 1 | |
| HK40006914A (en) | Method for electrochemical analysis by use of alternating output signals from two electrodes | |
| HK1179346B (en) | Biosensor system with signal adjustment | |
| HK1181850B (en) | Slope-based compensation including secondary output signals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230601 |